Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNUQAG)

Drug Name

CGP-029482 Drug Info

Synonyms

CGP-029482; CHEMBL92361; (5-OXO-5,6-DIHYDRO-INDOLO[1,2-A]QUINAZOLIN-7-YL)-ACETIC ACID; (5-oxo-5,6-dihydroindolo[1,2-a]quinazolin-7-yl)acetic acid; IQA; 1om1; AC1L9L3Y; SCHEMBL263731; BDBM11319; MolPort-006-167-937; HMS3229D05; ZINC2047511; CGP029482; AKOS005266257; DB01765; {5-oxo-6H-indolo[1,2-a]quinazolin-7-yl}acetic acid; 2-(5-oxo-6H-indolo[1,2-a]quinazolin-7-yl)acetic acid; [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 447682
CAS Number: CAS 391670-48-7
TTD Drug ID: DMNUQAG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Casein kinase II alpha (CSNK2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CX-4945	DMWE7B9	Coronavirus infection	1D92	Phase 2	[2]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[3]
EMODIN	DMAEDQG	Coronavirus Disease 2019 (COVID-19)	1D6Y	Terminated	[1]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[4]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[1]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[1]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[1]
PMID24900749C1a	DMZPUSO	Discovery agent	N.A.	Investigative	[5]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[6]
PMID22115617C2c	DMX5UKA	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Casein kinase II alpha (CSNK2A1)	TTER6YH	CSK21_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.
4	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
5	Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
6	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
7	CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.